BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio (ZURA)Zura Bio2026-06-25 13:46 ESTClinical readout

Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 Cash and cash

Open original release

Related news

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio to Participate in Upcoming Investor Conferences

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

View all latest news

Zura Bio

Zura Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ZURAZura Bio2026-06-26 17:24 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ZURAZura Bio2026-06-26 17:24 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-26 17:24 EST

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

ZURAZura Bio2026-06-26 17:24 EST

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

ZURAZura Bio2026-06-26 17:24 EST

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States